Endocrine

Articles

How do I Treat Hot Flashes in Cancer Survivors?

Oncology Times, Vol 33, # 21, 11/10/11, pp 24-25, First author: Loprinzi, Charles

Insulin and Obesity-Related Variables in Early Stage Breast Cancer: Correlations and Time Course of Prognostic Associations

Journal of Clinical Oncology, Vol. 30, # 2, 1/10/12, pp. 164-171, first author:  Goodwin, Pamela

Women's Experiences with Anti-estrogen Therapy to Treat Breast Cancer

Oncology Nursing Forum, Vol 39, # 1, Jan., 2012. First author: Flanagan, J.

Randomized Trial Using Gonadatropin-Releasing Hormone Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer

Journal of Clinical Oncology, Vol. 30, # 5, 2/10/12, pp. 533-538, First author: Munster, Pamela N.

Gynecologic Complications in Patients with Breast Cancer

M.D. Anderson Cancer Center Care Series: Breast Cancer, second edition, pp. 435-460

Premature Ovarian Failure and its Consequences: Vasomotor Symptoms, Sexuality, and Fertility

Journal of Clinical Oncology, Vol. 26, # 5, pp. 753-758, 2/10/08,

first author:  Schover, Leslie R.

Gynecologic Complications in Patients with Breast Cancer

The M.D. Anderson Cancer Care Series: Breast Cancer, second edition, pp. 435-460

first author:  Keeler, Elizabeth R.

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women with Estrogen Receptor- Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Journal of Clinical Oncology, Vol. 30, # 12, April 20, 2012, pp. 1268-1273. First author: Allred, D. Craig

Premature Aromatase Inhibitor Discontinuation is Commn

Oncology Nursing New, volume 6, # 4, June, 2012, p. 23. Author: Stein, Jill

Soy Phytoestrogens and Breast Cancer: An Enduring Dilemma

The ASCO Post, Volume 3, # 11, July 15, 2012, pp. 62-63.  Authors: Cassileth, Barrie R. and Yarett, Ian

Chemoprevention for Breast Cancer Risk Reduction: A Missed Opportunity

Dr. Victor G. Vogel, MD presents this data as part of the ASCO Breast Cancer Symposium, September 13-15, 2012.

Long-Term Effects of Continuing Tamoxifen to Ten Years versus Stopping at 5 Years after Diagnosis of Oestrogen-Receptor Positive Breast Cancer: ATLAS, a Randomised Trial

The Lancet Oncology, early online publication, December 5, 2012.  First author: Davies, Christina